


Trial design: Patients with diabetes and no known CVD were randomized to omega-3 fatty acid 840 mg daily (n = 7,740) vs. placebo (n = 7,740).



RESULTS

- Major adverse cardiovascular events (vascular death, MI, or stroke/TIA): 8.9% of the aspirin group vs. 9.2% of the placebo group (p = 0.55)
- Major adverse cardiovascular event or revascularization: 11.4% with omega-3 vs. 11.5% with placebo (p = NS)

CONCLUSIONS

- Among diabetic patients with no known CVD, omega-3 fatty acid supplementation was not beneficial
- Omega-3 fatty acids failed to reduce the incidence of major adverse cardiovascular events compared with placebo

ASCEND Study Collaborative Group. N Engl J Med 2018;Aug 26:[Epub]



AMERICAN
COLLEGE of
CARDIOLOGY®